Compare BLBD & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | VERA |
|---|---|---|
| Founded | 1927 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | BLBD | VERA |
|---|---|---|
| Price | $50.74 | $53.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $64.60 | ★ $76.60 |
| AVG Volume (30 Days) | 349.3K | ★ 1.8M |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.79 | N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $1,480,099,000.00 | N/A |
| Revenue This Year | $4.86 | N/A |
| Revenue Next Year | $3.41 | N/A |
| P/E Ratio | $13.08 | ★ N/A |
| Revenue Growth | ★ 9.87 | N/A |
| 52 Week Low | $30.04 | $18.53 |
| 52 Week High | $61.95 | $56.05 |
| Indicator | BLBD | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 80.23 |
| Support Level | $51.03 | $47.22 |
| Resistance Level | $52.89 | $56.05 |
| Average True Range (ATR) | 1.44 | 2.89 |
| MACD | 0.11 | 0.39 |
| Stochastic Oscillator | 38.06 | 85.61 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.